Adjuvant treatment in biliary tract cancer.
Biliary tract cancer (BTC)
adjuvant treatment
chemotherapy
prognostic factors
radiotherapy
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
04
08
2018
accepted:
12
08
2018
entrez:
4
2
2022
pubmed:
1
4
2019
medline:
1
4
2019
Statut:
ppublish
Résumé
Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Despite radical surgery, the five-year overall survival (OS) does not exceed 40% in the best series. Adjuvant treatments are widely used even though they have mainly been investigated in small retrospective series until recently. Available data suggest that chemotherapy with 5-fluorouracil (and relative prodrugs) or gemcitabine can reduce the risk of relapse and potentially improve patients' long-term outcome. The role of adjuvant radiotherapy seems to be confined to patients with positive surgical margins. In addition, patients with high-risk factors for relapse (nodal involvement and non-radical resection) benefit most from chemotherapy. Recent results from large randomized trials have clarified the benefit of adjuvant treatments and probably defined a new standard of care.
Identifiants
pubmed: 35117108
doi: 10.21037/tcr.2018.08.17
pii: tcr-08-S3-S289
pmc: PMC8798763
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
S289-S296Informations de copyright
2019 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2018.08.17). The series “Primary Liver Cancer” was commissioned by the editorial office without any funding or sponsorship. GB served as the unpaid Guest Editor of the series and serves as the unpaid editorial board member of Translational Cancer Research from Jan 2019 to Dec 2020. The authors have no other conflicts of interest to declare.
Références
J Clin Oncol. 2015 Aug 20;33(24):2617-22
pubmed: 25964250
Br J Surg. 2009 Aug;96(8):919-25
pubmed: 19591163
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
Ann Surg. 2007 May;245(5):755-62
pubmed: 17457168
Oncotarget. 2015 Jun 20;6(17):14744-53
pubmed: 26142706
Surg Today. 2017 Apr;47(4):403-415
pubmed: 27130463
World J Gastroenterol. 2014 Jul 14;20(26):8482-90
pubmed: 25024604
Ann Oncol. 2016 Apr;27(4):753
pubmed: 26920702
Cancer Discov. 2017 Sep;7(9):943-962
pubmed: 28818953
Ann Surg. 2011 Nov;254(5):824-29; discussion 830
pubmed: 22042474
J Hepatobiliary Pancreat Surg. 2002;9(5):569-75
pubmed: 12541042
Oncologist. 2016 May;21(5):600-7
pubmed: 27032872
JAMA. 2012 Jul 11;308(2):147-56
pubmed: 22782416
Ann Surg. 1995 Jun;221(6):788-97; discussion 797-8
pubmed: 7794082
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9
pubmed: 11573044
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
Cancer Chemother Pharmacol. 2012 May;69(5):1127-33
pubmed: 22207029
J Surg Oncol. 2017 May;115(6):696-703
pubmed: 28194791
J Gastroenterol Hepatol. 2013 Dec;28(12):1885-91
pubmed: 23829232
J Hepatobiliary Pancreat Sci. 2010 May;17(3):329-37
pubmed: 20464563
Arch Surg. 2012 Jan;147(1):26-34
pubmed: 22250108
Arch Surg. 2012 Dec;147(12):1107-13
pubmed: 22910846
Ann Surg. 2012 Aug;256(2):288-96
pubmed: 22580938
Ann Surg Oncol. 2011 Mar;18(3):651-8
pubmed: 20945107
J Gastrointest Surg. 2013 Nov;17(11):1917-28
pubmed: 24048613
Cancer. 2002 Oct 15;95(8):1685-95
pubmed: 12365016
J Hepatobiliary Pancreat Sci. 2011 May;18(3):443-52
pubmed: 21132443
J Clin Oncol. 2012 Jun 1;30(16):1934-40
pubmed: 22529261
Oncology. 2015;89(6):345-50
pubmed: 26418006
Cancer Treat Rev. 2012 Apr;38(2):111-9
pubmed: 21652148
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1495-501
pubmed: 18472359
Ann Surg. 2005 Sep;242(3):451-8; discussion 458-61
pubmed: 16135931
J Clin Oncol. 2011 Aug 10;29(23):3140-5
pubmed: 21730269